ArticleBlood advances2026

Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.

Christof Scheid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.